NCT06596135

Open-Label Extension Study of Setmelanotide

← Hub

Registry fields

Overall status: COMPLETED
Conditions: Obesity Associated With Defects in Leptin-melanocortin Pathway
Study type: INTERVENTIONAL
Phase: PHASE3
Primary purpose: TREATMENT
Intervention type: DRUG
Interventions: Setmelanotide
Lead sponsor: Rhythm Pharmaceuticals, Inc. (INDUSTRY)

Cached at: 2026-07-19 22:39:32

View on ClinicalTrials.gov

Brief summary

This is an open-label extension study designed to evaluate the long-term safety and tolerability of continued setmelanotide treatment in male and female patients ≥2 years of age who have completed or transitioned from a previous study with setmelanotide for rare genetic, syndromic, or acquired diseases of obesity upstream of the MC4R pathway.

Contact

Need a report or Korean medical writing based on this trial?

Request a report Medical writing Custom research report